Novo Nordisk A/S's biggest near-term growth driver is the obesity drug Wegovy (semaglutide), which represents a blockbuster-sized sales opportunity in an enormous untapped market, but the company needs to get the US launch back on track after a supply issue disrupted its initial plans.
Management assured investors during a Capital Markets Day on 3 March that supply constraints for Wegovy will be resolved in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?